August 21, 2012 — Zoll Medical Corp. announced it entered into an agreement to license Inovise Medical Inc.’s ambulatory Audicor technology as part of the advanced patient diagnostics in the LifeVest Wearable Defibrillator.
According to the American Heart Association, an estimated 83 million Americans are currently living with cardiovascular disease (CVD). CVD is responsible for one-third of all deaths annually, or more 2,200 deaths per day, in the United States. The risk of sudden cardiac death is the highest in the days and weeks following an acute cardiac event and during the period of medical therapy optimization, such as adjusting a pharmacologic regimen to treat heart failure.
The LifeVest Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing medical condition and until their permanent risk of SCA is established. The LifeVest protects patients during this time of highest risk while they are being optimized on medical therapy. A patient’s condition can improve from the benefits of medical therapy, including meaningful improvement in ejection fraction.
With the addition of the advanced diagnostic features from Inovise, LifeVest will be able to expand the suite of clinically meaningful patient information available to physicians and clinicians to support clinical decisions. In addition to ambulatory monitoring of ECG (electrocardiography), Inovise Medical’s Audicor technology analyzes heart sounds (acoustic cardiography) to provide more diagnostic capabilities and aid in assessing acute and chronic cardiac function for conditions such as heart failure and related co-morbidities.
“The integration of the advanced diagnostic technologies from Inovise with the LifeVest platform further emphasizes our ongoing commitment to providing physicians and clinicians with clinically meaningful tools to improve patient management and outcomes,” said Marshal Linder, president of Zoll.
Peter Bauer, president of Inovise Medical, added, “Inovise’s Audicor technology was developed through years of focused clinical research and algorithm development. We are pleased that, in conjunction with the success of Zoll’s LifeVest product line, physicians and clinicians will have access to our advanced diagnostics to monitor patients during the most vulnerable stages of their cardiac recovery. Inovise is proud to provide the benefits of our ambulatory diagnostic technology to the life-saving therapy of the LifeVest.”
For more information: www.audicor.com, www.zoll.com
September 05, 2024 
